RT Journal Article
T1 Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer.
A1 Martínez-González, Luis Javier
A1 Sánchez-Conde, Victor
A1 González-Cabezuelo, Jose María
A1 Antunez-Rodríguez, Alba
A1 Andrés-León, Eduardo
A1 Robles-Fernandez, Inmaculada
A1 Lorente, Jose Antonio
A1 Vázquez-Alonso, Fernando
A1 Alvarez-Cubero, María Jesus
K1 aggressiveness
K1 bioinformatic
K1 biomarkers
K1 precision medicine
K1 prostate cancer
AB MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways' AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs' expression patterns, such as miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs' analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D'Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR-93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR-93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.
SN 2227-9059
YR 2021
FD 2021-06-05
LK https://hdl.handle.net/10668/28431
UL https://hdl.handle.net/10668/28431
LA en
DS RISalud
RD Apr 17, 2025